MA26868A1 - Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases - Google Patents
Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinasesInfo
- Publication number
- MA26868A1 MA26868A1 MA26736A MA26736A MA26868A1 MA 26868 A1 MA26868 A1 MA 26868A1 MA 26736 A MA26736 A MA 26736A MA 26736 A MA26736 A MA 26736A MA 26868 A1 MA26868 A1 MA 26868A1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- unsubstituted
- pregabalin
- compounds
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
DEPOSANT Société dite : WARNER-LAMBERT COMPANY REVENDICATION DE PRIORITES US 25 Janvier 2000 60/178,261 ?Synthèse asymétrique de prégabaline" L'invention propose un procédé pour la préparation d'acide (S)-(+)-3-(aminomethyl)-5-méthylhexanoïque (prégabaline) ou d'un de ses sels par une synthèse par hydrogénation asymétrique. La prégabaline est utile pour le traitement et la prévention d'attaques cérébrales, de la douleur et de troubles psychotiques. La présente invention propose également des intermédiaires utiles dans la production de la prégabaline. Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases Il est décrit des composés de formule (I): dans laquelle R2, R7, R13, R14 et R15 représentent indépendamment l'hydrogène, ou un groupe alkyle inférieur (non)substitué, alcényle inférieur (non)substitué, alcynyle inférieur (non) substitué ou -(CH2)nR12 (non) substitué ; R5 représente un groupe halogéno, cyano, nitro, -R9, -NR9R10 ou -OR9 ; R6 représente un groupe halogéno, cyano, nitro -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9R10, -NR9COR10, alcényle inférieur (non)substitué ou alcynyle inférieur (non) substitué;R8 représente un groupe -CO2R13,-COR13, -CONR13R14, CSNR13R14,-C (NR13)NR14R15, -SO3R13, -SO2R13, -SO2NR13R14 -PO3R13R14, -POR13R14, -PO(NR13R14)2 R9 et R10 représentent indépendamment l'hydrogène ou un groupe alkyle inférieur (non)substitué; R11 représente un groupe hétéroaryle ou un groupe hétérocyclique ; R12 représente un groupe cycloalkyle, un groupe hétérocyclique, un groupe aryle ou un groupe hétéroaryle ; et n est égal à 0, 1, 2 ou 3. Ces composés et leurs compositions pharmaceutiques sont utiles pour le traitement de troubles de prolifération cellulaire, tels que le cancer et une resténose. Ces composés sont de puissants inhibiteurs de cdks et de kinases à médiation par des facteurs de croissance.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17826100P | 2000-01-25 | 2000-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26868A1 true MA26868A1 (fr) | 2004-12-20 |
Family
ID=22651853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA26736A MA26868A1 (fr) | 2000-01-25 | 2002-07-22 | Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1254137A1 (fr) |
| JP (1) | JP4047010B2 (fr) |
| KR (1) | KR20020065939A (fr) |
| CN (1) | CN1395578A (fr) |
| AP (1) | AP2002002586A0 (fr) |
| AR (1) | AR030044A1 (fr) |
| AU (1) | AU2542501A (fr) |
| BG (1) | BG106850A (fr) |
| BR (1) | BR0107751A (fr) |
| CA (1) | CA2397961C (fr) |
| CO (1) | CO5261549A1 (fr) |
| CR (1) | CR6706A (fr) |
| CZ (1) | CZ20022475A3 (fr) |
| DZ (1) | DZ3266A1 (fr) |
| EA (1) | EA200200643A1 (fr) |
| EE (1) | EE200200405A (fr) |
| GT (1) | GT200100016A (fr) |
| HN (1) | HN2001000013A (fr) |
| HU (1) | HUP0204141A3 (fr) |
| IL (1) | IL150545A0 (fr) |
| IS (1) | IS6443A (fr) |
| MA (1) | MA26868A1 (fr) |
| MX (1) | MXPA02007221A (fr) |
| NO (1) | NO20023527L (fr) |
| OA (1) | OA12161A (fr) |
| PA (1) | PA8510701A1 (fr) |
| PE (1) | PE20011066A1 (fr) |
| PL (1) | PL356802A1 (fr) |
| SK (1) | SK10632002A3 (fr) |
| SV (1) | SV2002000294A (fr) |
| TN (1) | TNSN01014A1 (fr) |
| WO (1) | WO2001055147A1 (fr) |
| YU (1) | YU50402A (fr) |
| ZA (1) | ZA200205879B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| CZ20031125A3 (cs) | 2000-10-23 | 2003-10-15 | Smithkline Beecham Corporation | Nové sloučeniny |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| PL373339A1 (en) | 2002-04-19 | 2005-08-22 | Smithkline Beecham Corporation | Novel compounds |
| MXPA05005547A (es) * | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
| US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| CN101014600A (zh) * | 2004-09-21 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 用作蛋白激酶抑制剂的6－(2－烷基－苯基)－吡啶并[2,3－d]嘧啶类 |
| US7479558B2 (en) | 2005-03-25 | 2009-01-20 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives |
| PE20100737A1 (es) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
| EP1868612A4 (fr) | 2005-03-25 | 2010-03-24 | Glaxo Group Ltd | Nouveaux composes |
| PE20100741A1 (es) | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
| FR2887882B1 (fr) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
| CN101243081A (zh) * | 2005-07-21 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物 |
| RU2008108898A (ru) * | 2005-08-09 | 2009-09-20 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназы |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| EP1914234A1 (fr) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| FR2910813B1 (fr) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| EP2112150B1 (fr) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Inhibiteurs Raf améliorés |
| EA201100879A1 (ru) * | 2008-12-01 | 2012-01-30 | Мерк Патент Гмбх | Производные пиридопиримидина в качестве ингибиторов аутотаксина |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP3733184B1 (fr) * | 2013-03-14 | 2023-08-30 | Icahn School of Medicine at Mount Sinai | Composés de pyrimidine pour l'utililisation dans la traitment de cancer |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR101671404B1 (ko) * | 2014-09-02 | 2016-11-02 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도 |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0790997B1 (fr) * | 1994-11-14 | 2000-03-22 | Warner-Lambert Company | 6-ARYLE PYRIDO[2,3-d]PYRIMIDINES ET NAPHTYRIDINES DESTINEES A L'INHIBITION DE LA PROLIFERATION CELLULAIRE INDUITE PAR PROTEINE TYROSINE KINASE |
| IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| ID27589A (id) * | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
-
2001
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/sk not_active Application Discontinuation
- 2001-01-23 GT GT200100016A patent/GT200100016A/es unknown
- 2001-01-23 AR ARP010100285A patent/AR030044A1/es not_active Application Discontinuation
- 2001-01-23 CA CA002397961A patent/CA2397961C/fr not_active Expired - Fee Related
- 2001-01-23 PL PL01356802A patent/PL356802A1/xx not_active Application Discontinuation
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/fr not_active Application Discontinuation
- 2001-01-23 EE EEP200200405A patent/EE200200405A/xx unknown
- 2001-01-23 IL IL15054501A patent/IL150545A0/xx unknown
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/hu unknown
- 2001-01-23 CN CN01804048A patent/CN1395578A/zh active Pending
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/pt not_active IP Right Cessation
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/cs unknown
- 2001-01-23 EA EA200200643A patent/EA200200643A1/ru unknown
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/es unknown
- 2001-01-23 EP EP01900591A patent/EP1254137A1/fr not_active Withdrawn
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/ja not_active Expired - Fee Related
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/fr active
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/es not_active Application Discontinuation
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 YU YU50402A patent/YU50402A/sh unknown
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/ko not_active Application Discontinuation
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/es not_active Application Discontinuation
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/es not_active Application Discontinuation
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/fr unknown
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/es unknown
- 2001-01-24 CO CO01005268A patent/CO5261549A1/es not_active Application Discontinuation
-
2002
- 2002-06-20 BG BG106850A patent/BG106850A/bg unknown
- 2002-06-25 IS IS6443A patent/IS6443A/is unknown
- 2002-07-17 CR CR6706A patent/CR6706A/es not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/fr unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26868A1 (fr) | Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases | |
| TNSN05250A1 (fr) | Pyrimidinones substituees | |
| TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
| US7745646B2 (en) | Bicyclic heteroaryl inhibitors of PDE4 | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| JP7450559B2 (ja) | 疾患の処置のためのｋｄｍ１ａ阻害剤 | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| MA26727A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant | |
| MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
| BR0201087A (pt) | Compostos antiinflamatórios de benzotriazol | |
| MA27438A1 (fr) | Piperazines heterocycliques substituees pour le traitement de la schizophrenie | |
| MA26991A1 (fr) | Triazolopyridines servant d'agents anti-inflammatoires | |
| MA30360B1 (fr) | Dérivés pyrimidiniques utilisés comme inhibiteurs de la pi3k | |
| MA27440A1 (fr) | Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf) | |
| MA26718A1 (fr) | Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| SI1678166T1 (sl) | Inhibitorji proteinske kinaze | |
| MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
| IL176546A0 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| MA28742B1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique | |
| EP1372657A2 (fr) | Traitement de maladies proliferatives au moyen d'inhibiteurs de eg5 |